A Phase I Dose Escalation Study on the Tolerability and Activity of TriN 2755 in Patients With Advanced Solid Tumors and Sarcomas Using Two Different Dosage Regimens

Trial Profile

A Phase I Dose Escalation Study on the Tolerability and Activity of TriN 2755 in Patients With Advanced Solid Tumors and Sarcomas Using Two Different Dosage Regimens

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs TRIN 2755 (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors TRIN Pharma
  • Most Recent Events

    • 17 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top